Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.

Launched by DR. STAVROULA RAKITZI · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to help people with treatment-resistant schizophrenia or treatment-resistant bipolar disorder—conditions that have not improved with standard treatments. The study is testing how well combining regular medication with two special recovery programs, called RECOVERYTRSGR for schizophrenia and RECOVERYTRSBDGR for bipolar disorder, can help patients manage their symptoms and improve their quality of life.

People who might join the study are adults aged 18 to 65 with a diagnosis of treatment-resistant schizophrenia or bipolar disorder, and who have an IQ of 80 or higher. Participants should not currently be struggling with substance abuse or recent hospital stays due to relapse, although those who have successfully treated substance abuse may still be eligible. If you join, you can expect to continue your usual medications while also taking part in these new recovery programs designed to support your overall recovery and well-being. The study is currently recruiting participants, and it welcomes adults of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria: For patients with treatment resistant schizophrenia:
• • age 18-65
• • IQ ≥ 80
• • Diagnosis TRS.
• Inclusion criteria for patients with treatment resistant bipolar disorder:
• • age 18-65
• • IQ ≥ 80
• • Diagnosis TRSBD.
• Exclusion Criteria: For patients with treatment resistant schizophrenia:
• • Substance abuse and head injury. If substance abuse is successfully treated, the participant will be accepted into our program.
• • Relapse and hospitalization.
• Exclusion criteria for patients with treatment resistant bipolar diosrder:
• • Substance abuse and head injuries. If substance abuse is successfully treated, the participant will be acknowledged into our program.
• • Relapse and hospitalization.